Breast cancer is a heterogeneous disease consisting of several distinct molecular tumor subtypes significantly differing in prognosis and therapeutic response, namely luminal A, luminal B, HER2-enriched and basal-like [1–4]. This evidence concerns the gene ERBB2 and breast carcinoma.